Barclays
PHIO icon

Barclays’s Phio Pharmaceuticals PHIO Stock Holding History

Barclays’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$7 – 5466
2025
Q1 		$7 Sell
5
-198
-98% -$366 ﹤0.01% 5186
2024
Q4 		$365 Buy
+203
New +$552 ﹤0.01% 5166
2014
Q3 		– Hold
0
– -$8K – 7782
2014
Q2 		– Hold
0
– – – 6940
2014
Q1 		– Hold
0
– – – 7280

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MYIA
Mount Yale Investment Advisors Denver, Colorado $4.31B AUM 21.13% 1-Year Est. Return

Barclays's PHIO Position: Q2 2025 in Review

Barclays sold out of Phio Pharmaceuticals (PHIO) in Q2 2025, closing a stake of 5 shares — an estimated $7 sold.

Barclays first reported a position in PHIO in Q4 2024 and held it in 2 quarters. The position peaked at $365 in Q4 2024. 11 funds tracked by Wall St. Rank hold PHIO as of Q2 2025.

  • Barclays reported no remaining Phio Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 5 Phio Pharmaceuticals shares in Q2 2025, an estimated $7.
  • Barclays first reported a position in Phio Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Barclays's Phio Pharmaceuticals position peaked at $365 in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.